by Dave Soulia. for FYIVT.com

When comparing healthcare systems globally, the refrain often heard is: “Look at Switzerland, Norway, or Canada. They have better healthcare than the U.S., and they spend less!” On the surface, these comparisons seem justified. Countries with universal systems often boast better life expectancy, lower costs, and broader access. However, this argument fails to account for one uncomfortable truth: much of the global affordability in healthcare relies on the United States paying exorbitant prices for medications, medical devices, and hospital services. Without the U.S. propping up this pricing system, these countries’ healthcare successes would look far less pristine.

How U.S. Subsidizes the Global Healthcare System

At the core of the issue is a simple fact: the United States pays far higher prices for pharmaceuticals, medical devices, and hospital services than any other nation. A RAND Corporation report showed that U.S. drug prices are, on average, 278% higher than prices in 33 other developed nations (Health Journalism). This isn’t because Americans consume more drugs—it’s because pharmaceutical companies charge far more for the exact same medications in the U.S. market.

Why? Because they can. Unlike countries such as Switzerland or Canada, where governments negotiate drug prices, the U.S. largely allows pharmaceutical companies to set prices unregulated. This effectively turns Americans into global subsidizers, as drug companies offset the lower prices negotiated elsewhere by charging sky-high prices in the U.S. As The International Business Times points out, Europeans benefit directly from U.S. overpayments, enjoying cheaper medications because American consumers and insurers cover the difference.

The situation is no different for medical devices. A study reported in Healthcare Finance News revealed that U.S. hospitals pay up to six times more for medical devices compared to their European counterparts. Again, the disparity stems from price negotiations. European governments cap costs, while U.S. hospitals—operating in a profit-driven, fragmented system—have little bargaining power and often face inflated prices.

This creates a global dynamic where affordable healthcare in countries like Switzerland or Norway depends on the U.S. footing the bill. If the U.S. suddenly paid Swiss-style prices for drugs and devices, pharmaceutical and medical companies would lose their most lucrative market. To recover, they would likely raise prices elsewhere, shattering the affordability that many European systems rely on.

But What About Outcomes?

Critics of U.S. healthcare often cite metrics like life expectancy and infant mortality rates to argue that other countries deliver better outcomes. Indeed, Switzerland and Norway outperform the U.S. on these fronts, but the reasons are more complex than healthcare spending alone.

First, lifestyle factors play a massive role. The U.S. has significantly higher rates of obesity, diabetes, and heart disease—conditions driven largely by diet, sedentary habits, and cultural norms. According to The BMJ, these chronic health conditions account for a substantial portion of America’s higher healthcare spending and poorer outcomes. Switzerland, by contrast, has lower obesity rates and a cultural emphasis on preventive care, walking, and healthier diets.

Second, access to preventive care is more equitable in countries with universal systems. In the U.S., high out-of-pocket costs discourage many Americans from seeking routine care, which allows chronic conditions to worsen and become more expensive to treat. Countries like Switzerland ensure basic preventive care is both accessible and affordable, which improves health outcomes over time.

However, even these advantages rely on controlled costs. If Switzerland or Norway had to pay the same drug and medical device prices as the U.S., their healthcare systems would face enormous financial strain. Universal access would become far more expensive, and their systems would likely adopt measures like rationing or cost-sharing to survive.

The Role of Innovation: Is the U.S. Paying for Progress?

Pharmaceutical companies defend high U.S. drug prices by arguing that the profits fund research and development (R&D) for new treatments. There’s some truth to this: the U.S. market generates the lion’s share of global pharma profits, and cutting those profits would likely reduce funding for new drugs.

However, the argument is overstated. As Vox reports, much of the pharmaceutical R&D spending goes toward “me-too drugs”—slightly modified versions of existing treatments designed to extend patents and maintain market exclusivity. In addition, the federal government and universities already fund a significant portion of foundational medical research, meaning taxpayers are subsidizing innovation twice: once through funding and again through high drug prices.

If the U.S. adopted price controls similar to Switzerland, pharmaceutical companies would face a reckoning. Some innovation might slow in the short term, but the industry would also be forced to become leaner and more efficient, investing in genuine breakthroughs rather than profit-padding strategies.

What If the U.S. Paid Swiss Prices?

If the U.S. negotiated Swiss-style prices for drugs, devices, and services, the impact would be profound. Americans would see:

1. Lower Healthcare Costs: Insurance premiums and out-of-pocket expenses would plummet as healthcare spending shrinks.
2. Expanded Access: Affordable prices would make universal or near-universal coverage far more feasible.
3. Economic Relief: Trillions of dollars would be freed up for wages, education, and infrastructure instead of being funneled into healthcare (MarketWatch).

Globally, however, the picture would shift dramatically. Pharmaceutical companies would lose their ability to rely on the U.S. to cover their profits, forcing them to raise prices elsewhere. Countries like Switzerland would face a harsh reality: their affordable systems are built, in part, on U.S. overpayments, and without that crutch, they’d need to make difficult adjustments.

The Bottom Line

The argument that countries like Switzerland have “better healthcare than the U.S.” ignores a key economic truth: their systems rely on price controls that the U.S. does not have. This dynamic allows Europeans to enjoy lower costs and better access, but it comes at the expense of U.S. consumers, who subsidize those benefits by paying top dollar for medications and devices.

If the U.S. adopted similar price regulations, Americans would finally see affordable, high-quality care—but the ripple effect would challenge the financial models of healthcare systems worldwide. The global healthcare economy is not a level playing field, and until that changes, comparisons between the U.S. and other nations remain incomplete at best.

To truly fix healthcare, the U.S. must demand the same fair prices that other countries enjoy—and in doing so, force the world to rethink its dependence on American overpayments to sustain their systems (Reason).